Table 1.
Associations between NKAIN1-SERINC2 region and different neuropsychiatric or neurological disorders
| SNP # | SNP # | SNP # | SNP # | Collapsing | Minimal | Most sig. | Minor allele frequency (N) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Human Diseases | Ethnicity | Dataset name | (total) | (p<0.05) | (p<α) | (q<0.05) | p value | p value | SNP | Gene | Affected | Unaffected |
| Alcoholism | EA (CC) | SAGE+COGA | 196 | 26 | 5 | 25 | 6.5×10−5 | 4.1×10−5 | rs35961897 | SERINC2 | 0.059 (1409) | 0.038 (1518) |
| Alcoholism | EAu (Fam) | OZ-ALC | 185 | 9 | 0 | 0 | 0.025 | 0.0196 | rs77840364 | SERINC2 | 0.015 (1645) | 0.012 (4793) |
| Alcoholism | AA (CC) | SAGE+COGA | 450 | 4 | 0 | 0 | 0.534 | 0.0141 | rs16834507 | SERINC2 | 0.040 (681) | 0.021 (508) |
| ADHD | CA (Fam) | IMAGE | 163 | 12 | 0 | 0 | 0.429 | 0.0017 | rs114467377 | NKAIN1 | 0.015 (924) | 0.014 (1833) |
| Autism | EA (Fam) | AGP | 189 | 13 | 0 | 0 | 0.977 | 0.0013 | rs114336824 | SERINC2 | 0.010 (1330) | 0.010 (2745) |
| Major Depression | CA (CC) | PRSC | 162 | 12 | 0 | 0 | 0.089 | 0.0010 | rs116080631 | SERINC2 | 0.028 (1805) | 0.015 (1820) |
| Bipolar Disorder | EA (CC) | BDO+GRU | 136 | 0 | 0 | 0 | 0.735 | 0.0902 | rs7541681 | SERINC2 | 0.125 (368) | 0.036 (1034) |
| Bipolar Disorder | EA (CC) | BARD+GRU | 138 | 5 | 0 | 0 | 0.714 | 0.0048 | rs55781513 | NKAIN1 | 0.026 (653) | 0.044 (1034) |
| Bipolar Disorder | AA (CC) | BARD+GRU | 351 | 7 | 0 | 0 | 0.312 | 0.0033 | rs114478713 | SERINC2 | 0.019 (141) | 0.001 (671) |
| Schizophrenia | EA (CC) | GAIN | 180 | 1 | 0 | 0 | 0.692 | 0.0080 | rs6659255 | SERINC2 | 0.073 (1351) | 0.046 (1378) |
| Schizophrenia | AA (CC) | GAIN | 441 | 20 | 0 | 0 | 0.816 | 0.0147 | rs80029070 | NKAIN1 | 0.025 (1195) | 0.038 (954) |
| Schizophrenia | EA (CC) | MGS_nonGAIN | 144 | 12 | 0 | 0 | 0.145 | 0.0024 | rs74872508 | SNRNP40 | 0.009 (1437) | 0.003 (1347) |
| Alzheimer's Disease | CA (Fam) | LOAD × 4 | 191 | 16 | 0 | 0 | 0.556 | 0.0057 | rs7417775 | SERINC2 | 0.052 (2298) | 0.037 (2921) |
| Alzheimer's disease | EA (CC) | GenADA | 113 | 10 | 0 | 0 | 0.514 | 0.0064 | rs76859788 | NKAIN1 | 0.012 (806) | 0.025 (782) |
| ALS | CA (CC) | GRU | 125 | 9 | 0 | 0 | 0.111 | 0.0111 | rs12024466 | ZCCHC17 | 0.004 (261) | 0.025 (246) |
| Early Onset Stroke | EA (CC) | GEOS × 3 | 144 | 1 | 0 | 0 | 0.246 | 0.0447 | rs13376139 | SNRNP40 | 0.008 (372) | 0.034 (430) |
| Early Onset Stroke | AA (CC) | GEOS × 3 | 431 | 54 | 0 | 0 | 0.080 | 0.0008 | rs56095638 | SERINC2 | 0.087 (309) | 0.038 (290) |
| Ischemic Stroke | CA (CC) | ISGS | 132 | 11 | 0 | 0 | 0.512 | 0.0041 | rs116007405 | SERINC2 | 0.028 (219) | 0.004 (266) |
| Parkinson's Disease | CA (CC) | NGRC | 187 | 3 | 0 | 0 | 0.745 | 0.0348 | rs114215404 | NKAIN1 | 0.002 (2000) | 0.005 (1986) |
| Parkinson's Disease | CA (CC) | PDRD+GRU | 142 | 0 | 0 | 0 | 0.088 | 0.0694 | rs75239059 | NKAIN1 | 0.003 (900) | 0.008 (867) |
| Parkinson's Disease | CA (CC) | lng_coriell_pd | 171 | 5 | 0 | 0 | 0.079 | 0.0195 | rs12564915 | SNRNP40 | 0.015 (940) | 0.039 (801) |
Only the most significant risk markers with minimal p values are listed. ADHD, Attention deficit hyperactivity disorder; ALS, Amyotrophic Lateral Sclerosis; AA, African-American; EA, European-American; EAu, European-Australian; CA, Caucasian; CC, case-control design; Fam, family-based design; N, sample size. Dataset names refer to dbGaP and references [GenADA: Li et al. Arch Neurol. 2008;65(1):45–53; Filippini et al. Neuroimage. 2009;44(3):724–728. AGP: The AGP Consortium. Nature. 2010;466(7204):368–372; Human Molecular Genetics. 2010;19(20):4072–4082; Nature Genetics. 2007;39(3):319–328]. The significance level (α) is corrected for the numbers of effective genetic markers (calculated by SNPSpD). Collapsing p values for entire NKAIN1-SERINC2 region were calculated using the program ARIEL.